Article Page

Abstract

ASARM-peptides are substrates and ligands for PHEX, the gene responsible for X-linked hypophosphatemic rickets (HYP). PHEX binds to the DMP1-ASARM-motif to form a trimeric-complex with α5β3-integrin on the osteocyte surface and this suppresses FGF23 expression. ASARM-peptide disruption of this complex increases FGF23 expression. A 4.2kDa peptide (SPR4) has been previously used that binds to ASARM-peptide and ASARM-motif to DMP1-PHEX interact and by assessing SPR4 for treating inherited hypophosphatemic rickets. Here, we discovered for the first time the GENEA-Bonespemitron-5527, a Computer-aided designed of a SPR4-peptide-mimetic pharmacophoric super-agonist for the regulation of bone metabolism utilizing Computational modelling of biomolecular simulation methods in structural biology interfaces between physics, chemistry and biology on an atomistic scalable literature computer-based discovery of an annotated SPR4-peptide-similar multi-molecular pharmacophoric reverse docked super-agonist scaffold as a canditate bone metabolism regulator.

Keywords

SPR4 peptide mimetic; pharmacophoric; super agonist; regulation; bone-metabolism; scalable Literature Based; β-catenin; Computational modelling; biomolecular systems; simulation methods; structural biology; interfaces; physics chemistry and biology in atomistic biomolecular simulation scalable literature;

Article Type

Research Article – Abstract

Publication history

Received: Sep 20, 2017
Accepted: Sep 25, 2017
Published: Oct 01, 2017

Citation

Grigoriadis Ioannis, Grigoriadis George, Grigoriadis Nikolaos, George Galazios (2017) Computational modelling of biomolecular simulation methods in structural biology interfaces between physics, chemistry and biology on an atomistic scalable literature computer-based discovery of an annotated SPR4-peptide-similar multi-molecular pharmacophoric reverse docked super-agonist scaffold as a canditate bone metabolism regulator.

Authors Info

Grigoriadis Nikolaos
Department of IT Computer Aided Personalized Myoncotherapy, Cartigenea-Cardiogenea, Neurogenea-Cellgenea, Cordigenea-HyperoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis Ioannis
Department of Computer Drug Discovery Science, BiogenetoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis George
Department of Stem Cell Bank and ViroGeneaTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

George Galazios
Professor of Obstetrics and Gynecology,
Democritus University of Thrace,
Komotini, Greece;

E-mail: biogeneadrug@gmail.com

File not available